Cargando…

Clinicopathologic study of 1176 salivary gland tumors in a Chinese population: Experience of one cancer center 1997–2007

Conclusion: Chinese patients have a higher rate of lymphoepithelial carcinoma (LEC) and salivary duct carcinoma (SDC). Comprehensive use of diagnostic modalities, neck dissection, and postoperative radiation will improve the treatment results for salivary gland tumors (SGTs). Objectives: To study th...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yu-Long, Zhu, Yong-Xue, Chen, Tong-Zhen, Wang, Yu, Sun, Guo-Hua, Zhang, Ling, Huang, Cai-Ping, Wang, Zhuo-Ying, Shen, Qiang, Li, Duan-Shu, Wu, Yi, Ji, Qing-Hai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Informa Healthcare 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3433083/
https://www.ncbi.nlm.nih.gov/pubmed/22497626
http://dx.doi.org/10.3109/00016489.2012.662715
Descripción
Sumario:Conclusion: Chinese patients have a higher rate of lymphoepithelial carcinoma (LEC) and salivary duct carcinoma (SDC). Comprehensive use of diagnostic modalities, neck dissection, and postoperative radiation will improve the treatment results for salivary gland tumors (SGTs). Objectives: To study the clinicopathological characteristics of SGTs in a Chinese population. Methods: The records of SGT patients operated in a tertiary cancer hospital of China were retrieved. Results: From December 1997 to December 2007, 289 malignant and 887 benign SGTs were operated at Cancer Hospital, Shanghai, China. Pleomorphic adenoma and Warthin's tumor were the most common types of SGT. Mucoepidermoid carcinoma (24.6% of malignant cases) and adenoid cystic carcinoma (18.0%) were the most frequent malignant cases, followed by acinic cell carcinoma (12.1%), LEC (9.7%), and SDC (9.3%). The sensitivity and specificity of ultrasound scan, fine needle aspiration biopsy, and frozen section were 58.3 and 88.6%, 87.2 and 96.7%, 86.9 and 99.6%, respectively. Neck dissections and postoperative radiation were carried out for 48.6 and 48.0% of carcinomas, respectively. The percentage of tumors by pathologic TNM stage were 23.7% for stage I, 32.9% for stage II, 17.3% for stage III, and 26.1% for stage IV. The 5-year overall survival rate was 88.0%.